JPRN-UMIN000004047Completed未知
Efficacy and Safety comparison of Sitagliptin and Glimepiride in elderly Japanese patients with type 2 diabetes - START-J: SiTAgliptin in eldeRly Trial in Japan
Japan Association for Diabetes Education and Care0 sites900 target enrollmentStarted: August 16, 2010Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Enrollment
- 900
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 60years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1.Active proliferative retinopathy or maculopathy requiring treatment 2.Liver dysfunction (>x2 of upper normal limit), moderate or severe renal dysfunction(serum Cr>1.5mg/dL in male, Cr>1.3mg/dL in female, GFR<30), severe cardiac disease (NYHA III or IV), malignancy or uncontrolled hypertension (treated or untreated) as judged by the Investigator 3.Mental incapacity (including moderate or severe dementia) precluding adequate understanding and/or cooperation as judged by the Investigator 4.Recurrent hypoglycaemia or hypoglycaemic unawareness as judged by the investigator 5.Previous history of severe allergy to pharmaceutical products 6.Systemic glucocorticoids users or potential users 7.Suspected type 1 diabetes (including SPIDDM) or positive anti-GAD antibody 8.Any condition that the investigator considers a potential obstacle to trial participation and/or data analysis
Investigators
Similar Trials
Completed
Phase 2
Sitagliptin and Pioglitazon effects in the treatment of diabetesIRCT2015061619554N4Vice chancellor for research; Zanjan University of Medical Sciences160
Not yet recruiting
Phase 4
A clinical study to understand the combined effects ofSitagliptin & metformin, in comparison to Glimepiride & metformin treatment in type 2 diabetes patientsCTRI/2024/04/065877Dr Keerthi Rajan M
Completed
Not Applicable
Comparison of efficacy and safety of sitagliptin or ipragliflozin in type 2 diabetic patients with insulin therapyType 2 diabetesJPRN-UMIN000014139Yokohama City University70
Completed
Not Applicable
Comparison of effectiveness of sitagliptin and nateglinide in type 2 diabetes.type 2 diabetesJPRN-UMIN000006278Japanese Red Cross Medical Center40
Recruiting
Phase 2
?Evaluation the effects of Sitagliptin administration in patients with COVID-19Pneumonia of COVID-19.COVID-19, virus identifiedU07.1IRCT20200420047147N1Shahid Beheshti University of Medical Sciences84